MedTrace Logo

Carvedilol and Micro T-Wave Alternans in Hypertensives With Chronic Kidney Disease

NCT00638222 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2014-11-13

Study results available
· View outcomes & findings →

Summary

Evaluate effectiveness of Carvedilol CR on Micro T-Wave Alternans in high risk hypertensives

Conditions

Interventions

OTHER

Carvedilol and Placebo

All enrolled participants were randomized to receive Carvedilol or Placebo in a 2-way crossover design. Each intervention was administered over 8 weeks before switching to the alternative intervention. The study was terminated early, and data were not unblinded so participants cannot be reported separately.

Sponsors & Collaborators

  • GlaxoSmithKline

    collaborator INDUSTRY

  • University of Toledo Health Science Campus

    lead OTHER

Principal Investigators

  • Christopher Cooper,, MD · University of Toledo

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-05-31
Primary Completion
2010-12-31
Completion
2010-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00638222 on ClinicalTrials.gov